keyword
https://read.qxmd.com/read/38655553/discovery-and-biosynthesis-of-bacterial-drimane-type-sesquiterpenoids-from-streptomyces-clavuligerus
#1
JOURNAL ARTICLE
Dongxu Zhang, Wenyu Du, Xingming Pan, Xiaoxu Lin, Fang-Ru Li, Qingling Wang, Qian Yang, Hui-Min Xu, Liao-Bin Dong
Drimane-type sesquiterpenoids (DMTs) are characterized by a distinctive 6/6 bicyclic skeleton comprising the A and B rings. While DMTs are commonly found in fungi and plants, their presence in bacteria has not been reported. Moreover, the biosynthetic pathways for DMTs have been primarily elucidated in fungi, with identified P450s only acting on the B ring. In this study, we isolated and characterized three bacterial DMTs, namely 3β-hydroxydrimenol ( 2 ), 2α-hydroxydrimenol ( 3 ), and 3-ketodrimenol ( 4 ), from Streptomyces clavuligerus ...
2024: Beilstein Journal of Organic Chemistry
https://read.qxmd.com/read/38651886/a-novel-member-of-drug-metabolite-transporter-dmt-family-efflux-pump-sa00565-contributes-to-tetracycline-antibiotics-resistance-in-staphylococcus-aureus-usa300
#2
JOURNAL ARTICLE
Daiyu Li, Yan Ge, Ning Wang, Yun Shi, Gang Guo, Jing Zhang, Quanming Zou, Qiang Liu
Drug efflux systems have recently been recognized as a significant mechanism responsible for multidrug resistance in bacteria. In this study, we described the identification and characterization of a new chromosomally encoded efflux pump (SA00565) in Staphylococcus aureus . SA00565, which belongs to the drug/metabolite transporter (DMT) superfamily, was predicted to be a 10-transmembrane segment transporter. To evaluate the role of sa00565 in resistance, we generated sa00565 gene deletion mutant (Δ sa00565 ) and assessed its susceptibility to 35 different antibiotic treatments...
April 23, 2024: Microbiology Spectrum
https://read.qxmd.com/read/38648420/discovery-and-structure-activity-relationships-of-2-5-dimethoxyphenylpiperidines-as-selective-serotonin-5-ht-2a-receptor-agonists
#3
JOURNAL ARTICLE
Emil M Ro Rsted, Anders A Jensen, Gints Smits, Karla Frydenvang, Jesper L Kristensen
Classical psychedelics such as psilocybin, lysergic acid diethylamide (LSD), and N,N -dimethyltryptamine (DMT) are showing promising results in clinical trials for a range of psychiatric indications, including depression, anxiety, and substance abuse disorder. These compounds are characterized by broad pharmacological activity profiles, and while the acute mind-altering effects can be ascribed to their shared agonist activity at the serotonin 2A receptor (5-HT2A R), their apparent persistent therapeutic effects are yet to be decidedly linked to activity at this receptor...
April 22, 2024: Journal of Medicinal Chemistry
https://read.qxmd.com/read/38641878/clinical-effectiveness-of-coronavirus-disease-2019-vaccination-in-patients-with-multiple-sclerosis-stratified-by-disease-modifying-treatment
#4
JOURNAL ARTICLE
Marijke De Troyer, Ann Van Remoortel, Jeroen Van Schependom, Laetitia Della Faille, Marie B D'hooghe, Gertjan Peeters, Guy Nagels, Miguel D'haeseleer
BACKGROUND AND PURPOSE: Coronavirus disease 2019 (COVID-19) vaccination has been associated with a dampened humoral and/or cellular immune response in patients with multiple sclerosis (MS) who were concurrently on disease-modifying treatment (DMT) with B-cell depleting agents or sphingosine-1-phosphate receptor modulators (S1PRMs). Our main goal was to investigate the impact of these DMT classes on the clinical effectiveness of COVID-19 vaccination. METHODS: Since March 2020, demographics and clinical data of patients with MS who developed COVID-19 have been collected at the Belgian National MS Centre in Melsbroek...
April 19, 2024: European Journal of Neurology
https://read.qxmd.com/read/38638671/a-review-of-bruton-s-tyrosine-kinase-inhibitors-in-multiple-sclerosis
#5
REVIEW
Laura Airas, Robert A Bermel, Tanuja Chitnis, Hans-Peter Hartung, Jin Nakahara, Olaf Stuve, Mitzi J Williams, Bernd C Kieseier, Heinz Wiendl
Bruton's tyrosine kinase (BTK) inhibitors are an emerging class of therapeutics in multiple sclerosis (MS). BTK is expressed in B-cells and myeloid cells, key progenitors of which include dendritic cells, microglia and macrophages, integral effectors of MS pathogenesis, along with mast cells, establishing the relevance of BTK inhibitors to diverse autoimmune conditions. First-generation BTK inhibitors are currently utilized in the treatment of B-cell malignancies and show efficacy in B-cell modulation. B-cell depleting therapies have shown success as disease-modifying treatments (DMTs) in MS, highlighting the potential of BTK inhibitors for this indication; however, first-generation BTK inhibitors exhibit a challenging safety profile that is unsuitable for chronic use, as required for MS DMTs...
2024: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/38638559/the-effect-of-multiple-sclerosis-therapy-on-gut-microbiota-dysbiosis-a-longitudinal-prospective-study
#6
JOURNAL ARTICLE
Andreea-Cristina Paraschiv, Vitalie Vacaras, Cristina Nistor, Cristiana Vacaras, Stefan Strilciuc, Dafin F Muresanu
Gut microbiota has complex immune functions, related to different pathologies, including multiple sclerosis (MS).This study evaluated the influence of treatments on gut microbiota in people with MS (PwMS). The research comprised 60 participants, including 39 PwMS and 21 healthy controls (HC). Among the PwMS, 20 were prescribed a disease-modifying therapy (DMT), either interferon beta1a or teriflunomide, while 19 received a combination of classical DMT and an immunoglobulin Y (IgY) supplement. For each participant, two sets of gut samples were collected: one at the study's outset and another after two months...
2024: Microbial Cell
https://read.qxmd.com/read/38638312/prospective-observational-study-to-evaluate-treatment-satisfaction-and-effectiveness-in-patients-with-relapsing-multiple-sclerosis-starting-cladribine-tablets-cladreal-in-italy
#7
JOURNAL ARTICLE
Massimo Filippi, Laura Ferrè, Chiara Zanetta, Caterina Rizzi, Gabriella Pessina, Francesco Assogna, Maria A Rocca
Disease-modifying therapies (DMTs) for multiple sclerosis (MS) reduce relapse frequency, magnetic resonance imaging (MRI) activity, and slow disability progression. Numerous DMTs are approved for relapsing forms of MS although real-world data on patient-reported outcomes (PROs) and quality of life (QoL) are needed to inform treatment choice. Immune reconstitution therapy with cladribine tablets is a highly effective treatment for relapsing MS (RMS). We present the protocol for an observational study to prospectively assess the effectiveness of cladribine tablets on clinical and MRI parameters as well as on PROs, including treatment satisfaction, QoL, sleep quality, self-perceived health, fatigue, and physical function...
2024: Frontiers in Neurology
https://read.qxmd.com/read/38634840/trips-through-the-skin-reviewing-cutaneous-drug-reactions-to-psychedelics-and-hallucinogens
#8
REVIEW
Syed Minhaj Rahman, Yousef Salem, Aamir Hussain
<u> <i/> </u>Although psychedelic and hallucinogenic substances have gained popularity for therapeutic use, their dermatologic adverse effects are poorly characterized. This review characterizes the cutaneous reactions associated with psychedelic and hallucinogenic drugs. A review of PubMed and Scopus was conducted from the inception of databases to August 31, 2023. Search terms included drug names and classes (cannabis, MDMA, ecstasy, 3,4-methylenedioxymethamphetamine, psychedelics, hallucinogens, peyote, marijuana, lysergic acid diethylamide, LSD, ketamine, dimethyltryptamine, DMT, phencyclidine, PCP, dextromethorphan, psilocybin, and ayahuasca), and dermatosis terms (dermatitis, contact dermatitis, drug eruption, skin reaction, and urticaria)...
April 17, 2024: Dermatitis
https://read.qxmd.com/read/38633535/respiratory-function-in-adult-patients-with-spinal-muscular-atrophy-treated-with-nusinersen-a-monocenter-observational-study
#9
JOURNAL ARTICLE
Claudia Diana Wurster, Zeljko Uzelac, Jens Dreyhaupt, Joachim Schuster, Johannes Dorst, Albert Christian Ludolph, Kurt Wollinsky
BACKGROUND/OBJECTIVE: Insufficiency of respiratory muscles is the most important reason for mortality in the natural history of SMA. Thus, improvement or stabilization of respiratory function by disease-modifying therapies (DMT) is a very important issue. METHODS: We examined respiratory function using forced vital capacity (FVC) in 42 adult SMA patients (2 SMA type 1, 15 SMA type 2, 24 SMA type 3, 1 SMA type 4, median age 37 years, range 17-61 years) treated with nusinersen for a median of 22...
2024: Frontiers in Neurology
https://read.qxmd.com/read/38630948/glial-activity-load-on-pet-reveals-persistent-smoldering-inflammation-in-ms-despite-disease-modifying-treatment-18f-pbr06-study
#10
JOURNAL ARTICLE
Tarun Singhal, Steven Cicero, Eero Rissanen, John Ficke, Preksha Kukreja, Steven Vaquerano, Bonnie Glanz, Shipra Dubey, William Sticka, Kyle Seaver, Marie Kijewski, Alexis M Callen, Renxin Chu, Kelsey Carter, David Silbersweig, Tanuja Chitnis, Rohit Bakshi, Howard L Weiner
PURPOSE OF THE REPORT: 18F-PBR06-PET targeting 18-kDa translocator protein can detect abnormal microglial activation (MA) in multiple sclerosis (MS). The objectives of this study are to develop individualized mapping of MA using 18F-PBR06, to determine the effect of disease-modifying treatment (DMT) efficacy on reducing MA, and to determine its clinical, radiological, and serological correlates in MS patients. PATIENTS AND METHODS: Thirty 18F-PBR06-PET scans were performed in 22 MS patients (mean age, 46 ± 13 years; 16 females) and 8 healthy controls (HCs)...
April 17, 2024: Clinical Nuclear Medicine
https://read.qxmd.com/read/38629297/dissonance-in-the-face-of-alzheimer-s-disease-breakthroughs-clinician-and-lay-stakeholder-acceptance-concerns-and-willingness-to-pay-for-emerging-disease-modifying-therapies
#11
JOURNAL ARTICLE
Irina Kinchin, Sharon Walsh, Rachel Dinh, Margaret Kapuwa, Sean P Kennelly, Ann-Marie Miller, Ann Nolan, Sean O'Dowd, Laura O'Philbin, Suzanne Timmons, Iracema Leroi
BACKGROUND: Introducing new disease-modifying therapies (DMTs) for Alzheimer's disease demands a fundamental shift in diagnosis and care for most health systems around the world. Understanding the views of health professionals, potential patients, care partners and taxpayers is crucial for service planning and expectation management about these new therapies. AIMS: To investigate the public's and professionals' perspectives regarding (1) acceptability of new DMTs for Alzheimer's disease; (2) perceptions of risk/benefits; (3) the public's willingness to pay (WTP)...
April 17, 2024: British Journal of Psychiatry
https://read.qxmd.com/read/38626360/effect-of-prior-treatment-with-fingolimod-on-early-and-late-response-to-rituximab-ocrelizumab-in-patients-with-multiple-sclerosis
#12
JOURNAL ARTICLE
Lisa Graille-Avy, Clemence Boutiere, Camille Rigollet, Marine Perriguey, Audrey Rico, Sarah Demortiere, Pierre Durozard, Frederic Hilezian, Frederic Vely, Pierre Bertault-Peres, Jean Pelletier, Adil Maarouf, Bertrand Audoin
BACKGROUND AND OBJECTIVES: Real-life studies noted that the risk of disease activity in multiple sclerosis (MS) after switching to rituximab (RTX) or ocrelizumab (OCR) may be unequal depending on prior disease-modifying therapy (DMT), with a higher risk associated with fingolimod (FING). METHODS: We performed a retrospective analysis of a structured prospective data collection including all consecutive patients with relapsing MS who were prescribed RTX/OCR in the MS center of Marseille...
May 2024: Neurology® Neuroimmunology & Neuroinflammation
https://read.qxmd.com/read/38622900/the-use-of-dance-and-movement-for-the-embodied-healing-of-interpersonal-trauma-in-women-and-girls-a-systematic-review
#13
REVIEW
Catherine X Liang, Thema Bryant
Interpersonal trauma is a pervasive issue with devastating consequences for women and girls of diverse identities. Research has shown that there are many potential physiological consequences for experiencing trauma, and as such, treatment for trauma should incorporate the body. Dance/Movement Therapy (DMT) has been emerging in the current literature as one body-oriented treatment approach effective in helping women and girls heal from interpersonal trauma. This review uses textual narrative evidence synthesis to examine how practitioners are currently using DMT for this population, what treatment outcomes have been observed, and what the racial/ethnic identities and international contexts are for survivors who have benefited from DMT...
April 15, 2024: Trauma, Violence & Abuse
https://read.qxmd.com/read/38618323/disease-modifying-treatments-and-their-future-in-alzheimer-s-disease-management
#14
REVIEW
Blake Smith, Raymond L Ownby
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by memory impairment, a loss of cholinergic neurons, and cognitive decline that insidiously progresses to dementia. The pathoetiology of AD is complex, as genetic predisposition, age, inflammation, oxidative stress, and dysregulated proteostasis all contribute to its development and progression. The histological hallmarks of AD are the formation and accumulation of amyloid-β plaques and interfibrillar tau tangles within the central nervous system...
March 2024: Curēus
https://read.qxmd.com/read/38616782/treatment-algorithms-of-relapsing-multiple-sclerosis-an-exploration-based-on-the-available-disease-modifying-therapies-in-china
#15
REVIEW
Jun Guo, Jiayong Wu, Lihua Wang, Hongbo Liu, Xiaomu Wu, Huan Yang, Wenyu Li, Honghao Wang, Bitao Bu, Chunsheng Yang, Hongyu Zhou, Shougang Guo, Yinan Zhao, Zhanhang Wang, Chunyang Li, De-Cai Tian, Sheng Chen, Huiru Xue, Yanlin Zhang, Yongfeng Xu, Hui Liang, Zhe Wu, Yu Zhang, Qiang Dong, Jiawei Wang, Chao Quan
Multiple sclerosis (MS) was defined as a rare disease in China due to its low prevalence. For a long time, interferon β was the only approved disease-modifying therapy (DMT). Since the first oral DMT was approved in 2018, DMT approval accelerated, and seven DMTs were approved within 5 years. With an increasing number of DMTs being prescribed in clinical practice, it is necessary to discuss the standardized MS treatment algorithms depending on the disease activity and DMT availability. In this review paper, more than 20 Chinese experts in MS have reviewed the therapeutic progress of MS in China and worldwide and discussed algorithms for treating relapsing MS (RMS) based on the available DMTs in China, providing insights for establishing the standardized RMS treatment algorithms in this country...
2024: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/38616411/phase-1-placebo-controlled-single-ascending-dose-trial-to-evaluate-the-safety-pharmacokinetics-and-effect-on-altered-states-of-consciousness-of-intranasal-bpl-003-5-methoxy-n-n-dimethyltryptamine-benzoate-in-healthy-participants
#16
JOURNAL ARTICLE
James Jonathan Rucker, Claire Roberts, Mathieu Seynaeve, Allan H Young, Ben Suttle, Takahiro Yamamoto, Anna O Ermakova, Fiona Dunbar, Frank Wiegand
AIMS: To investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BPL-003, a novel intranasal benzoate salt formulation of 5-methoxy- N,N -dimethyltryptamine (5-MeO-DMT), in healthy participants. METHODS: In all, 44 psychedelic-naïve participants enrolled in the double-blind, placebo-controlled single ascending dose study (1-12 mg BPL-003). Concentrations of 5-MeO-DMT and its pharmacologically active metabolite, bufotenine, were determined in plasma and urine...
April 14, 2024: Journal of Psychopharmacology
https://read.qxmd.com/read/38608516/sars-cov-2-infection-increases-long-term-multiple-sclerosis-disease-activity-and-all-cause-mortality-in-an-underserved-inner-city-population
#17
JOURNAL ARTICLE
Roham Hadidchi, Stephen H Wang, David Rezko, Sonya Henry, Patricia K Coyle, Tim Q Duong
BACKGROUND: Although certain subsets patients with multiple sclerosis (MS), an immune-mediated disorder, are at higher risk of worse acute COVID-19 outcomes compared to the general population, it is not clear whether SARS-CoV-2 infection impacts long-term outcomes compared with MS patients without COVID-19 infection. OBJECTIVES: This study investigated MS disease activity and mortality 3.5 years post SARS-CoV-2 infection and compared with MS patients without COVID-19...
April 8, 2024: Multiple Sclerosis and related Disorders
https://read.qxmd.com/read/38600715/the-potential-of-5-methoxy-n-n-dimethyltryptamine-in-the-treatment-of-alcohol-use-disorder-a-first-look-at-therapeutic-mechanisms-of-action
#18
REVIEW
Stephan C Tap
Alcohol use disorder (AUD) remains one of the most prevalent psychiatric disorders worldwide with high economic costs. Current treatment options show modest efficacy and relapse rates are high. Furthermore, there are increases in the treatment gap and few new medications have been approved in the past 20 years. Recently, psychedelic-assisted therapy with psilocybin and lysergic acid diethylamide has garnered significant attention in the treatment of AUD. Yet, they require significant amounts of therapist input due to prolonged subjective effects (~4-12 h) leading to high costs and impeding implementation...
April 2024: Addiction Biology
https://read.qxmd.com/read/38598954/ocrelizumab-b-cell-depletion-has-no-effect-on-herv-rna-expression-in-pbmc-in-ms-patients
#19
JOURNAL ARTICLE
Rachael Tarlinton, Radu Tanasescu, Claire Shannon-Lowe, Bruno Gran
BACKGROUND: Epstein barr virus (EBV) infection of B cells is now understood to be one of the triggering events for the development of Multiple Sclerosis (MS), a progressive immune-mediated disease of the central nervous system. EBV infection is also linked to expression of human endogenous retroviruses (HERVs) of the HERV-W group, a further risk factor for the development of MS. Ocrelizumab is a high-potency disease-modifying treatment (DMT) for MS, which depletes B cells by targeting CD20...
March 30, 2024: Multiple Sclerosis and related Disorders
https://read.qxmd.com/read/38598282/effect-of-%C3%AE-tubulin-acetylation-on-the-doublet-microtubule-structure
#20
JOURNAL ARTICLE
Shun Kai Yang, Shintaroh Kubo, Corbin Steven Black, Katya Peri, Daniel Dai, Thibault Legal, Melissa Valente-Paterno, Jacek Gaertig, Khanh Huy Bui
Acetylation of α-tubulin at the lysine 40 residue (αK40) by αTAT1/MEC-17 acetyltransferase modulates microtubule properties and occurs in most eukaryotic cells. Previous literatures suggest that acetylated microtubules are more stable and damage resistant. αK40 acetylation is the only known microtubule luminal post-translational modification site. The luminal location suggests that the modification tunes the lateral interaction of protofilaments inside the microtubule. In this study, we examined the effect of tubulin acetylation on the doublet microtubule (DMT) in the cilia of Tetrahymena thermophila using a combination of cryo-electron microscopy, molecular dynamics, and mass spectrometry...
April 10, 2024: ELife
keyword
keyword
11061
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.